Long-Term Nicotine Replacement Therapy | Clinical Trial
The goal of the trial was to evaluate different treatment durations of nicotine replacement therapy among smokers.
Contribution to the Literature: This trial failed to show that prolonged nicotine replacement therapy (>8 weeks) led to higher rates of smoking cessation.
Smokers were randomized to nicotine replacement therapy (transdermal nicotine patch 21 mg) for 8 weeks (standard therapy; n = 180) versus 24 weeks (extended therapy; n = 173) versus 52 weeks (maintenance therapy; n = 172). In addition, all participants received 12 standardized behavioral counseling sessions.
- Smokers (≥10 cigarettes per day) at least 18 years of age who were willing to stop smoking
- Total number of enrollees: 525
- Duration of follow-up: 52 weeks
- Mean patient age: 46 years
- Percentage female: 51%
- Psychotic or bipolar disorder
- Unable to communicate in English
- Pregnant or lactating women
At 24 weeks, 21.7% of the standard therapy group was abstinent within the previous 7 days (CO2 confirmed) versus 27.2% of the extended/maintenance therapy group (p = 0.17).
- At 24 weeks: 9.4% of the standard therapy group was continuously abstinent (self-report) versus 11.3% of the extended/maintenance therapy group (p = 0.79)
- Severe adverse effects at 30 weeks: 4.9% with standard therapy versus 2.6% with extended therapy, versus 6.8% with maintenance therapy
Among smokers, >8 weeks of nicotine replacement therapy did not significantly increase rates of smoking cessation compared with 8 weeks. However, long-term nicotine replacement therapy appeared to be safe.
Schnoll RA, Goelz PA, Veluz-Wilkins A, et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med 2015;Feb 23:[Epub ahead of print].
Keywords: Nicotine, Smoking, Smoking Cessation, Tobacco Use Cessation Products, Counseling, Primary Prevention
< Back to Listings